Stephen H Leppla Selected Research

anthrax toxin (anthrax lethal factor)

1/2022	Receptor-enhanced immunogenicity of anthrax protective antigen is primarily mediated by capillary morphogenesis Protein-2.
12/2019	Bacillus anthracis Virulence Regulator AtxA Binds Specifically to the pagA Promoter Region.
1/2019	Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
9/2017	Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.
10/2016	Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting.
10/2016	A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection.
1/2016	Tumor Targeting and Drug Delivery by Anthrax Toxin.
11/2015	An anthrax toxin variant with an improved activity in tumor targeting.
10/2015	Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
3/2015	A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen H Leppla Research Topics

Disease

105	Anthrax 01/2022 - 02/2002
36	Neoplasms (Cancer) 10/2019 - 02/2002
23	Infections 01/2021 - 06/2002
21	Edema (Dropsy) 01/2022 - 11/2005
9	Melanoma (Melanoma, Malignant) 01/2016 - 01/2003
6	Shock 12/2015 - 02/2004
5	Inflammation (Inflammations) 01/2020 - 03/2006
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2015 - 10/2004
3	Peritonitis 01/2016 - 01/2014
2	Hypoxia (Hypoxemia) 01/2021 - 09/2003
2	Toxemia 05/2019 - 01/2004
2	Gout 01/2016 - 03/2015
2	Hypotension (Low Blood Pressure) 01/2009 - 05/2007
2	Sepsis (Septicemia) 06/2007 - 02/2005
1	Pain (Aches) 01/2022
1	Inhalation anthrax 05/2019
1	Parkinson Disease (Parkinson's Disease) 05/2019
1	Plague (Bubonic Plague) 10/2018
1	Astrocytoma (Pilocytic Astrocytoma) 05/2016
1	Bacterial Infections (Bacterial Infection) 06/2014
1	Toxoplasmosis 02/2014

Drug/Important Bio-Agent (IBA)

36	anthrax toxin (anthrax lethal factor)IBA 01/2022 - 02/2002
35	AntigensIBA 01/2022 - 01/2003
32	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2002
18	InflammasomesIBA 12/2020 - 02/2008
16	Virulence Factors (Pathogenicity Factors)IBA 01/2020 - 07/2003
14	edema factorIBA 01/2022 - 06/2008
12	Peptide Hydrolases (Proteases)FDA Link 01/2020 - 02/2002
11	Matrix Metalloproteinases (MMPs)IBA 10/2019 - 06/2005
10	VaccinesIBA 10/2018 - 07/2002
10	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 09/2017 - 01/2003
10	Mitogen-Activated Protein KinasesIBA 10/2015 - 01/2003
9	anthrax toxin receptorsIBA 12/2012 - 09/2005
8	ExotoxinsIBA 06/2014 - 02/2002
7	Plasminogen Activators (Plasminogen Activator)IBA 10/2015 - 01/2003
7	Monoclonal AntibodiesIBA 09/2013 - 02/2005
6	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2020 - 01/2003
6	FurinIBA 10/2019 - 01/2004
6	AntibodiesIBA 08/2015 - 08/2002
5	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2021 - 11/2005
5	Anti-Bacterial Agents (Antibiotics)IBA 10/2016 - 10/2005
5	Diphtheria ToxinIBA 07/2009 - 02/2002
4	Neutralizing AntibodiesIBA 01/2022 - 06/2002
4	Phosphotransferases (Kinase)IBA 12/2020 - 07/2003
4	Pharmaceutical PreparationsIBA 01/2019 - 10/2005
4	Peptides (Polypeptides)IBA 01/2015 - 02/2002
4	GelatinasesIBA 01/2010 - 03/2008
4	CytokinesIBA 06/2008 - 02/2004
3	Bacterial ToxinsIBA 01/2022 - 05/2003
3	EnzymesIBA 04/2013 - 02/2002
3	LigandsIBA 11/2004 - 08/2002
2	AntitoxinsIBA 01/2021 - 01/2011
2	adefovirIBA 01/2021 - 03/2011
2	Metalloproteases (Metalloproteinases)IBA 05/2019 - 09/2008
2	Plague VaccineIBA 10/2018 - 01/2017
2	Single-Domain AntibodiesIBA 10/2016 - 03/2015
2	NucleotidesIBA 01/2016 - 02/2014
2	ProdrugsIBA 10/2015 - 01/2006
2	Uric Acid (Urate)IBA 03/2015 - 01/2014
2	Capsules (Microcapsules)IBA 01/2015 - 01/2011
2	Caspase 1 (ICE Protease)IBA 02/2014 - 12/2010
2	FlagellinIBA 01/2014 - 10/2012
2	Immunotoxins (Immunotoxin)IBA 01/2013 - 08/2003
2	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2013 - 08/2009
2	von Willebrand FactorIBA 12/2012 - 07/2009
2	LipidsIBA 10/2012 - 02/2003
2	DNA (Deoxyribonucleic Acid)IBA 02/2012 - 05/2003
2	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2008 - 02/2008
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2004 - 10/2004
1	CarrageenanIBA 01/2022
1	Botulinum Toxins (Botulinum Toxin)IBA 01/2022
1	Formaldehyde (Formol)FDA Link 01/2022
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 12/2019
1	Therapeutic UsesIBA 05/2019
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 05/2019
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 05/2019
1	Subunit VaccinesIBA 10/2018
1	NanovaccinesIBA 10/2018
1	Combined VaccinesIBA 10/2018
1	Capsid Proteins (Capsid Protein)IBA 10/2018
1	BiothraxIBA 10/2018
1	Biological Warfare AgentsIBA 10/2018
1	Nimodipine (Modus)FDA LinkGeneric 01/2016
1	sulforaphaneIBA 01/2016
1	leucine receptorIBA 01/2016
1	raxibacumabIBA 12/2015
1	Serine Proteases (Serine Protease)IBA 10/2015
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 10/2015
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 08/2015
1	15-deoxyprostaglandin J2IBA 03/2015
1	Indicators and Reagents (Reagents)IBA 09/2014
1	Cytotoxins (Cytolysins)IBA 09/2014
1	MicroRNAs (MicroRNA)IBA 09/2014
1	Amino Acids FDA Link 04/2014
1	Bicarbonates (Hydrogen Carbonate)IBA 03/2014
1	Leucine (L-Leucine)FDA Link 02/2014

Therapy/Procedure

27	Therapeutics 01/2022 - 02/2002
3	Drug Therapy (Chemotherapy) 08/2003 - 08/2002
1	Analgesia 01/2022
1	Intravenous Administration 10/2019